Moneycontrol PRO
you are here: HomeNewsBusiness

Rakesh Jhunjhunwala-promoted Akasa Air’s holding company SNV Aviation registered using Vinay Dubey's address

Last week, Dube said an application for a no-objection certificate has been sought from the aviation ministry for SNV Aviation, which will be the holding company for the proposed budget airline Akasa Air.

August 04, 2021 / 08:29 PM IST
Rakesh Jhunjhunwala

Rakesh Jhunjhunwala

SNV Aviation, the proposed holding company for Rakesh Jhunjhunwala-promoted Akasa Air, has been registered with the Registrar of Companies (ROC) using the personal address of former Jet Airways chief executive officer Vinay Dube, data from the ROC accessed by Moneycontrol showed.

Last week, Dube had repertedly said an application for a no-objection certificate has been sought from the aviation ministry for SNV Aviation, which will be the holding company for the proposed budget airline Akasa Air.

ALSO READ: Is Rakesh Jhunjhunwala’s Akasa another pie in the sky?

According to the data with the ROC, SNV Aviation has been registered to Dubey's personal address at Sewri in Mumbai and Sanjay Dube, Vinay Dube and Shonali Dube are listed as its directors.

On August 4, CNBC-TV18 reported that the Rakesh Jhunjhunwala-promoted Akasa Air has received no-objection certificate from the Civil Aviation Ministry and the Directorate General of Civil Aviation.


COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

According to the report, Akasa Air is most likely to opt for a Boeing fleet of narrow-body aircraft and is expected to receive an air operator permit post aircraft acquisition. The airline is aiming to begin operations by end of 2021.

Earlier on July 28, reports emerged that Jhunjhunwala was planning to have 70 planes in four years for the new airline venture that he has decided to back. Jhunjhunwala is expected to own nearly 40 percent of the stake in the new airline and is considering to invest $35 million in the venture.

Yaruqhullah Khan
ISO 27001 - BSI Assurance Mark